IRF8 Antibody
Code | Size | Price |
---|
PSI-3401-0.02mg | 0.02mg | £150.00 |
Quantity:
PSI-3401-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Western Blot (WB)
Images
Documents
Further Information
Additional Names:
IRF8 Antibody: Interferon Regulatory Factor, Interferon Consensus Sequence Binding Protein, H-ICSBP, ICSBP1, ICSBP, IRF-8, Interferon Consensus Sequence-Binding Protein, IMD32A, IMD32B
Application Note:
IRF8 antibody can be used for detection of IRF8 by Western blot at 1 μg/mL. For immunofluorescence start at 10 μg/mL.
Antibody validated: Western Blot in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
IRF8 Antibody: Interferons (IFN)s are involved in a multitude of immune interactions during viral infections and play a major role in both the induction and regulation of innate and adaptive antiviral mechanisms. During infection, host-virus interactions signal downstream molecules such as transcription factors such as IFN regulatory factor-3 (IRF3) which can act to stimulate transcription of IFN-alpha/beta genes. Unlike IRF3, IRF8 appears to act as a negative regulator of IFN-induced genes in most cases, but IRF8 mediates activation of NF-κB by the toll-like receptor 9 (TLR9) after stimulation by unmethylated CpG DNA in dendritic cells. Finally, it has been shown that IRF8 decreases bcl-2 expression and thus may play a role in chronic myelogenous leukemia.
Background References:
- Malmgaard L. Induction and regulation of IFNs during viral infections. J. Interferon & Cyto. Res. 2004; 24:439-54
- Weisz A, Marx P, Sharf R, et al. The human interferon consensus sequence binding protein (H-ICSBP) is a negative regulator of enhancer elements common to interferon inducible genes. J. Biol. Chem. 1992; 267:25589-96.
- Nelson N, Marks MS, Driggers PH, et al. Interferon consensus sequence-binding protein, a member of the interferon regulatory factor family, suppresses interferon-induced gene transcription. Mol. Cell. Biol. 1993; 13:588-99.
- Tsujimura H, Tamura T, Kong HJ, et al. Toll-like receptor 9 signaling activates NF-κB through IFN regulatory factor-8/IFN consensus sequence binding protein in dendritic cells. J. Immunol. 2004; 172:6820-7.
Buffer:
IRF8 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
IRF8 antibody was raised against a peptide corresponding to 16 amino acids near the carboxy terminus of human IRF8.
The immunogen is located within the last 50 amino acids of IRF8.
The immunogen is located within the last 50 amino acids of IRF8.
NCBI Gene ID #:
3394
NCBI Official Name:
interferon regulatory factor 8
NCBI Official Symbol:
IRF8
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
Q02556
Purification:
IRF8 Antibody is affinity chromatography purified via peptide column.
Research Area:
Chemokines & Cytokines
Swissprot #:
Q02556
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
Product Name | Product Code | Supplier | IRF8 Peptide | PSI-3401P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|